Abstract
Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.
Originalsprache | Englisch |
---|---|
Zeitschrift | European Heart Journal |
ISSN | 0195-668X |
DOIs | |
Publikationsstatus | Elektronische Veröffentlichung vor Drucklegung - 02.09.2024 |